Comt inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives.
D000818:Animals; D000978:Antiparkinson Agents / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D003863:Depression / Q000188:drug therapy / Q000209:etiology; D004409:Dyskinesia, Drug-Induced / Q000150:complications / Q000188:drug therapy; D005544:Forecasting; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000517:prevention & control; D011605:Psychoses, Substance-Induced / Q000150:complications / Q000188:drug therapy
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018696:Neuroprotective Agents; D007980:Levodopa; D002394:Catechol O-Methyltransferase